ClinicalTrials.gg
RecruitingNCT04629547SToP-ADUpdated Jul 13, 2026

Sleep Trial to Prevent Alzheimer's Disease

A Phase 2 interventional study of Suvorexant 20 mg and Placebo in Sleep and Alzheimer Disease, sponsored by University of Minnesota. Recruiting at 1 site in United States. Open to participants aged 65 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-13.

Sponsored by University of Minnesota · Phase 2, Interventional, and Prevention

How we know

From the registry’s dates

  • Started May 2022; still recruiting 4 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Alzheimer Disease by University of Minnesota — 3 open to participants now, 4 under way, none of them phase 3. Alzheimer Disease · University of Minnesota.

Planned enrollment
9th of 14
120 · median 162
Started
2022
with 2 others
Phase 2
3 of 16
2 open now
Registered
11th of 16
by date

Among the 16 studies in Alzheimer Disease by University of Minnesota, this one is the 9th largest by planned enrollment of the 14 interventional ones that give a count, is one of 3 that started in 2022, is one of 3 in phase 2, and was the 11th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

3 of the 16 studies in Alzheimer Disease by University of Minnesota are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 65 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Alzheimer Disease by University of Minnesota, or all of them as a file.
02

Study summary

The purpose of this study is to determine if treatment with the sleep aid suvorexant can decrease the rate of amyloid-β (Aβ) accumulation in the brain.

Read the detailed description

This study will investigate if long-term treatment with suvorexant will slow amyloid-β accumulation in the brain. Amyloid-β is a protein involved in the disease process leading to Alzheimer's disease. This study will evaluate if suvorexant can decrease the amount of amyloid-beta detected by plasma pT217/T217.

03

Conditions studied

  • Sleep
  • Alzheimer Disease

Keywords

  • poor sleep
  • Amyloid-Beta
  • Insomnia
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

  • Male or female.
  • Any race or ethnicity.
  • Participants must be age ≥65 years and able to sign .
  • Global Clinical Dementia Rating (CDR) 0.
  • Willing and able to undergo study procedures.

Exclusion Criteria:

  • History of reported symptoms suggestive of restless legs syndrome, narcolepsy or other central disorder of hypersomnolence, or parasomnia
  • STOP-Bang score >6 for participants without PAP
  • Untreated OSA with AHI ≥15 on home sleep test
  • Treated sleep apnea with PAP non-compliance

    • PAP compliance is defined as >= 4 hours per night >70% of the nights
  • Plasma A-beta and tau test with a plasma p-tau 217% ≤ 1.19
  • Stroke.
  • Chronic kidney disease defined as patients with markers of kidney damage or of \< 45 ml/min/1.73m2.
  • Hepatic impairment defined as and/or ALT > 2x (normal limits AST: 11-47 IU/L, ALT: 6-53 IU/L).
  • /AIDS.
  • History of substance abuse or alcohol abuse in the proceeding 6 months.
  • Regular alcohol consumption 3 or more days a week over the last 6 months. Regular alcohol consumption is defined as having more than 2 alcoholic beverages within 3 hours of bedtime. Participants that agree to reduce alcohol consumption during the study may not be excluded.
  • History of presence of any medical condition, behavioral or psychiatric disorder, or surgical history based on medical record or participant report that could affect the safety of the participant or interfere with study assessments or in the judgement of the Principal-Investigator (PI) if participant is not a good candidate.
  • Has any medical condition that, in the PI's opinion, could increase risk to the participant, limit the participant's ability to tolerate the research procedures, or interfere with the collection/analysis of the data. Potential medical conditions that will be exclusionary at the PI's discretion:

    • Cardiovascular disease requiring medication except for controlled hypertension.
    • Pulmonary disease.
    • Type I diabetes.
    • Neurologic or psychiatric disorder requiring medication.
    • Tobacco use.
    • Use of sedating medications.
    • Use of medications that interact with suvorexant (if cannot be discontinued)
    • Abnormal safety labs
  • History of current suicidal ideations.
  • Currently pregnant or breast-feeding.
  • In the opinion of the PI, the participant should be excluded due to an abnormal physical examination.
  • Must not have participated in any clinical trial involving a study drug or device within the 30-days prior to study enrollment.
  • Must not participate in another drug or device study prior to the end of this study participation.

Exclusion criteria for optional lumbar punctures

-• to lumbar puncture (anticoagulants; bleeding disorder; allergy to lidocaine or disinfectant; prior central nervous system or lower back surgery).

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Poor sleep treatment group

    60 participants will be randomized to take suvorexant 20mg daily at h.s. for 18-24 months

    Drug: Suvorexant 20 mg

  • Placebo comparator
    Poor sleep control grop

    60 participants will be randomized to take placebo daily at h.s. for 18-24 months

    Drug: Placebo

Interventions

  • DrugSuvorexantStudies of SuvorexantSuvorexant pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Suvorexant 20mg will be taken nightly for 24 months.

    Also known as: Belsomra

  • DrugPlacebo

    Placebo will be taken nightly for 24 months.

    Also known as: inactive pill, sugar pill

06

What researchers measure

Primary outcomes

  1. Change from baseline in Amyloid-β accumulation measured by plasma pT217/T217 in participants treated with 20 mg suvorexant compared to placebo

    Blood collection

    Time frame: 18-24 months

Secondary outcomes

  1. Change in plasma Amyloid-β compared to placebo

    Blood collection

    Time frame: 18-24 months

  2. Change in CSF Amyloid-β compared to placebo

    Cerebrospinal fluid collection

    Time frame: 18-24 months

  3. Change in plasma tau compared to placebo

    Blood collection

    Time frame: 18-24 months

  4. Change in CSF tau compared to placebo

    Cerebrospinal fluid collection

    Time frame: 18-24 months

  5. Change in plasma p-tau compared to placebo

    Blood collection

    Time frame: 18-24 months

  6. Change in CSF p-tau compared to placebo

    Cerebrospinal fluid collection

    Time frame: 18-24 months

  7. Change in cognitive performance compared to placebo

    Measured by a cognitive composite consisting of the Digit Symbol Substitution Test, Animal Naming, Trails B and the Free and Cued Selective Reminding Test. Each test will be z-scored and then averaged together to make the composite.

    Time frame: 18-24 months

  8. Change in transcriptomics compared to placebo

    blood and optional CSF collection

    Time frame: 18-24 months

  9. Change in metabolomics compared to placebo

    blood and optional CSF collection

    Time frame: 18-24 months

  10. Change in proteomics compared to placebo

    blood and optional CSF collection

    Time frame: 18-24 months

  11. Change in gut microbiome compared to placebo

    optional stool sample collection

    Time frame: 18-24 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Noh MY, Kwon HS, Kwon MS, Nahm M, Jin HK, Bae JS, Kim SH. Biomarkers and therapeutic strategies targeting microglia in neurodegenerative diseases: current status and future directions. Mol Neurodegener. 2025 Jul 10;20(1):82. doi: 10.1186/s13024-025-00867-4. PubMed 40640892 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2022 (actual). Primary completion is estimated for May 2028, 72 months after the start.

Of 128 non-industry phase 2 interventional studies under Alzheimer Disease, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 69. This study's planned 72 months is above that.

Counting every sponsor, half of 259 studies reached it within 37 months; a quarter within 21 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2020
First posted
Nov 16, 2020
StartActual
May 25, 2022
Primary completionEst.
May 2028
CompletionEst.
May 2028
Last update
Jul 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04629547
Collaborators
Good Ventures, Merck Sharp & Dohme LLC
Responsible party
Sponsor
First posted
Nov 16, 2020
Start date
May 25, 2022
Primary completion
May 2028 (estimated)
Completion
May 2028 (estimated)
Last update
Jul 13, 2026

Study contacts

Cristina Toedebusch, BS
Contact
toedebuschc@wustl.edu
3147470646
Chloe Meehan, MA
Contact
cmeehan@wustl.edu
3142730878
Brendan Lucey, MD
principal investigator · Washington Univeristy School of Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Suvorexant

Start the discussion